Tranexamic versus aminocaproic acids in patients with total hip arthroplasty: a retrospective study

• Published in: BMC musculoskeletal disorders 2022-11, Vol.23 (1), p.1-999, Article 999
• Main Authors: Xie, Hui, Yang, Yu-Shen, Tian, Si-miao, Wang, Ben-jie, Fu, Wei-min, Cheng, Liang-liang, Jiang, Nan-nan, Gu, Guishan, Zhao, De-wei
• Format: Article
• Language: English
• Subjects: Acids; Aminocaproic acids; Antifibrinolytic agents; Arthritis; Blood; Blood transfusion; Blood transfusions; Bone surgery; Comparative analysis; Cost control; Cost savings; Disease; Dosage and administration; Epsilon aminocaproic acid; Hematocrit; Hemoglobin; Hip; Hospitals; Intravenous administration; Joint replacement surgery; Length of stay; Musculoskeletal diseases; Patients; Surgery; Total hip arthroplasty; Tranexamic acid; Transfusion; Variance analysis
• ISSN: 1471-2474; 1471-2474
• DOI: 10.1186/s12891-022-05922-5

Background Recently, tranexamic acid (TXA) and epsilon aminocaproic acid (EACA) have been applied in total hip arthroplasty (THA). However, doubts in clinicians' minds about which medicine is more efficient and economical in THA need to be clarified. Therefore, this study compared the efficacy and cost of the intraoperative administration of TXA and EACA per surgery in decreasing perioperative blood transfusion rates in THA. Methods This study enrolled patients who underwent THA between January 2019 to December 2020. A total of 295 patients were retrospectively divided to receive topical combined with intravenous TXA (n = 94), EACA (n = 97) or control (n = 104). The primary endpoints included transfusions, estimated perioperative blood loss, cost per patient and the drop in the haemoglobin and haematocrit levels. Results Patients who received EACA had greater total blood loss, blood transfusion rates, changes in HGB levels and mean cost of blood transfusion per patient (P < 0.05) compared with patients who received TXA. In addition, both TXA and EACA groups had significantly fewer perioperative blood loss, blood transfusion, operation time and changes in haemoglobin and haematocrit levels than the control group (P < 0.05). Cost savings in the TXA and EACA groups were 736.00 RMB and 408.00 RMB per patient, respectively. Conclusions The application of perioperative antifibrinolytics notably reduces the need for perioperative blood transfusions. What's more, this study demonstrated that TXA is superior to EACA for decreasing blood loss and transfusion rates while at a lower cost per surgery. These results indicate that TXA may be the optimum antifibrinolytics for THA in Chinese area rather than EACA. Keywords: Total hip arthroplasty, Transfusion, Tranexamic acid, Epsilon aminocaproic acid, Cost savings